Premium
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre‐B acute lymphoblastic leukemia
Author(s) -
Glover Jason M.,
Loriaux Marc,
Tyner Jeffrey W.,
Druker Brian J.,
Chang Bill H.
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23383
Subject(s) - dasatinib , medicine , lymphoblast , lymphoblastic leukemia , in vitro , cancer research , precursor cell , leukemia , oncology , cell culture , imatinib , genetics , myeloid leukemia , biology
Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B‐cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B‐cell precursor ALL. Pediatr Blood Cancer 2012;59:576–579. © 2011 Wiley Periodicals, Inc.